Literature DB >> 19484238

The same genetic defect in three Tunisian families with Bernard Soulier syndrome: a probable founder Stop mutation in GPIbβ.

Basma HadjKacem1, Henda Elleuch, Ramzi Trigui, Jalel Gargouri, Ali Faouzi Gargouri.   

Abstract

GPIbα, GPIbβ, and GPIX are three candidate genes for a rare genetic bleeding disorder named Bernard Soulier syndrome (BSS). These genes are unique in the genome and encode for glycoprotein subunits of the GPIb-IX complex. Quantitative or qualitative deficiency in this complex is often associated with BSS. Here, we report the novel variant of BSS in which Ser23 of GPIbβ is substituted by a Stop codon causing a premature termination of translation, recently described in one family. This genetic defect is revealed in three unrelated BSS patients. The pedigree was determined for two families (F1 and F2) and revealed the homozygosity of the mutation in the two patients and its heterozygosity in parents. In the third family, the patient DNA was heterozygote with the same Ser23 Stop mutation in addition to two missense heterozygote mutations (Asp 51 Gly) and (Ala 55 to Pro). We studied the effect of the Ser23 Stop mutation on the expression of the complex. Our findings confirm that the identified GPIbβ mutation is responsible for the BSS phenotype and hampers the GPIb-IX complex to form on the platelets' surface. Regarding the scarcity of the BSS syndrome, the occurrence of the same mutation in three unrelated families would suggest a BSS founder mutation in Tunisia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19484238     DOI: 10.1007/s00277-009-0763-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  24 in total

Review 1.  Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.

Authors:  Eugen Koren; Holly W Smith; Elizabeth Shores; Gopi Shankar; Deborah Finco-Kent; Bonita Rup; Yu-Chen Barrett; Viswanath Devanarayan; Boris Gorovits; Shalini Gupta; Thomas Parish; Valerie Quarmby; Michael Moxness; Steven J Swanson; Gary Taniguchi; Linda A Zuckerman; Christopher C Stebbins; Anthony Mire-Sluis
Journal:  J Immunol Methods       Date:  2008-01-29       Impact factor: 2.303

2.  Epitope mapping by surface plasmon resonance.

Authors:  Pär Säfsten
Journal:  Methods Mol Biol       Date:  2009

3.  The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum.

Authors:  Daniel T Mytych; Stephon La; Troy Barger; John Ferbas; Steven J Swanson
Journal:  J Pharm Biomed Anal       Date:  2008-11-27       Impact factor: 3.935

Review 4.  Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.

Authors:  Gopi Shankar; Viswanath Devanarayan; Lakshmi Amaravadi; Yu Chen Barrett; Ronald Bowsher; Deborah Finco-Kent; Michele Fiscella; Boris Gorovits; Susan Kirschner; Michael Moxness; Thomas Parish; Valerie Quarmby; Holly Smith; Wendell Smith; Linda A Zuckerman; Eugen Koren
Journal:  J Pharm Biomed Anal       Date:  2008-09-19       Impact factor: 3.935

5.  Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.

Authors:  James B Bussel; David J Kuter; Vinod Pullarkat; Roger M Lyons; Matthew Guo; Janet L Nichol
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

Review 6.  New thrombopoietic growth factors.

Authors:  David J Kuter
Journal:  Blood       Date:  2007-02-08       Impact factor: 22.113

7.  Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.

Authors:  James N George; Susan D Mathias; Ronald S Go; Matthew Guo; David H Henry; Roger Lyons; Robert L Redner; Lawrence Rice; Martin R Schipperus
Journal:  Br J Haematol       Date:  2008-11-11       Impact factor: 6.998

8.  Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab.

Authors:  James A Lofgren; Sripriya Dhandapani; Jason J Pennucci; Christina M Abbott; Daniel T Mytych; Arunan Kaliyaperumal; Steven J Swanson; Michael C Mullenix
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

9.  Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.

Authors:  David J Kuter; James B Bussel; Roger M Lyons; Vinod Pullarkat; Terry B Gernsheimer; Francis M Senecal; Louis M Aledort; James N George; Craig M Kessler; Miguel A Sanz; Howard A Liebman; Frank T Slovick; J Th M de Wolf; Emmanuelle Bourgeois; Troy H Guthrie; Adrian Newland; Jeffrey S Wasser; Solomon I Hamburg; Carlos Grande; François Lefrère; Alan Eli Lichtin; Michael D Tarantino; Howard R Terebelo; Jean-François Viallard; Francis J Cuevas; Ronald S Go; David H Henry; Robert L Redner; Lawrence Rice; Martin R Schipperus; D Matthew Guo; Janet L Nichol
Journal:  Lancet       Date:  2008-02-02       Impact factor: 79.321

10.  A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.

Authors:  Yukari Shirasugi; Kiyoshi Ando; Satoshi Hashino; Toshiro Nagasawa; Yoshiyuki Kurata; Yuji Kishimoto; Koji Iwato; Tomoko Ohtsu; Dietmar P Berger
Journal:  Int J Hematol       Date:  2009-06-20       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.